Approval · Notice of Compliance 22624 · 2019
EXELON PATCH: Notice of Compliance 22624
Issued September 10, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22624
- Date
- September 10, 2019
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of drug substance manufacturing site and drug substance intermediate manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON PATCH | Not yet assigned | — |
Medicinal ingredients
- RIVASTIGMINE 9 MG per PATCH
- RIVASTIGMINE 18 MG per PATCH
- RIVASTIGMINE 27 MG per PATCH